BUSINESS COMBINATIONS AND ACQUISITIONS (Details 2) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Non-recurring adjustments to pro forma information
Net income	$ (33,895)	$ 40,321	$ (12,565)	$ 116,238
Transaction costs
Non-recurring adjustments to pro forma information
Net income			(24,900)	24,900
Compensation expense related to severance and retention agreements
Non-recurring adjustments to pro forma information
Net income			(2,100)	2,100
Trius Therapeutics, Inc. | Transaction costs
Non-recurring adjustments to pro forma information
Net income			(24,900)	24,900
Trius Therapeutics, Inc. | Stock-based compensation expense related to the acceleration of vesting of previously unvested awards
Non-recurring adjustments to pro forma information
Net income			$ (24,000)	$ 24,000